Cargando…

CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis

CUGBP Elav‐like family member 2(CELF2) plays crucial roles in the development and activation of T cell. However, the impacts of CELF2 on tumour‐infiltrating immune cells (TIICs) and clinical outcomes of tumours remain unclear. In this study, we found that elevated CELF2 expression was markedly corre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Libo, Liu, Zaoqu, Liu, Long, Guo, Chunguang, Jiao, Dechao, Li, Lifeng, Zhao, Jie, Han, Xinwei, Sun, Yuling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335674/ https://www.ncbi.nlm.nih.gov/pubmed/34288370 http://dx.doi.org/10.1111/jcmm.16791

Ejemplares similares

TTN/OBSCN ‘Double‐Hit’ predicts favourable prognosis, ‘immune‐hot’ subtype and potentially better immunotherapeutic efficacy in colorectal cancer
por: Liu, Zaoqu, et al.
Publicado: (2021)

The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer
por: Liu, Zaoqu, et al.
Publicado: (2021)

Somatic mutations in homologous recombination pathway predict favourable prognosis after immunotherapy across multiple cancer types
por: Liu, Zaoqu, et al.
Publicado: (2021)

Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer
por: Liu, Zaoqu, et al.
Publicado: (2021)

Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer
por: Liu, Zaoqu, et al.
Publicado: (2021)

A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2022)

Editorial: Using multi-omics to develop new strategies to improve prognosis and immunotherapy outcomes in cancers
por: Cao, Chenxi, et al.
Publicado: (2023)

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2023)

Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression
por: Zhou, Xueliang, et al.
Publicado: (2020)

Editorial: The role of multi-omics variants in tumor immunity and immunotherapy
por: Chen, Shuang, et al.
Publicado: (2022)

Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management
por: Liu, Zaoqu, et al.
Publicado: (2021)

Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratification and frontline therapies in pancreatic cancer
por: Wang, Libo, et al.
Publicado: (2022)

A Comparative Study of Self-Expandable Metallic Stent Combined with Double (125)I Seeds Strands or Single (125)I Seeds Strand in the Treatment of Advanced Perihilar Cholangiocarcinoma with Malignant Obstructive Jaundice
por: Li, Zhaonan, et al.
Publicado: (2021)

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?
por: Hendrickx, Wouter, et al.
Publicado: (2015)

A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Engineering neoantigen vaccines to improve cancer personalized immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Computational Recognition and Clinical Verification of TGF-β-Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment
por: Xu, Hui, et al.
Publicado: (2022)

SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer
por: Weng, Siyuan, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A|IDO1
por: Liu, Zaoqu, et al.
Publicado: (2021)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Molecular Characterization and Clinical Relevance of ALDH2 in Human Cancers
por: Ma, Bo, et al.
Publicado: (2022)

MR-guided microwave ablation of hepatocellular carcinoma (HCC): is general anesthesia more effective than local anesthesia?
por: Li, Zhaonan, et al.
Publicado: (2021)

Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets
por: Guo, Aiyuan, et al.
Publicado: (2022)

Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer
por: Liu, Zaoqu, et al.
Publicado: (2022)

Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer
por: Liu, Zaoqu, et al.
Publicado: (2021)

Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy
por: Chen, Yu, et al.
Publicado: (2022)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

2450-MHz microwave ablation of liver metastases under 3.0 T wide-bore magnetic resonance guidance: a pilot study
por: Xu, Kaihao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p9coblkios8oqrbr231nlp4h2k